Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma: Is it a significant prognostic factor?

被引:3
作者
Shin, Hae Jin [1 ]
Moon, Hee Seok [2 ]
Kang, Sun Hyung [2 ]
Sung, Jae Kyu [2 ]
Jeong, Hyun Yong [2 ]
Kim, Seok Hyun [2 ]
Lee, Byung Seok [2 ]
Kim, Ju Seok [2 ]
Yun, Gee Young [2 ]
机构
[1] Republ Korea Air Force, Aerosp Med Ctr, Dept Internal Med, Div Gastroenterol, Cheongwon Gun, Chungcheongbuk, South Korea
[2] Chungnam Natl Univ, Chungnam Natl Univ Hosp, Sch Med, Div Gastroenterol,Dept Internal Med, 282 Munhwa Ro, Daejeon 35015, South Korea
关键词
definitive chemoradiotherapy; endoscopic traversability; esophageal cancer; malignant stricture; prognostic factor; DEFINITIVE CHEMORADIOTHERAPY; CLINICAL-IMPLICATIONS; FOLLOW-UP; CANCER; ULTRASONOGRAPHY; SURVIVAL; CHEMORADIATION; ADENOCARCINOMAS; MORTALITY; ACCURACY;
D O I
10.1097/MD.0000000000009441
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to evaluate the prognostic impact of endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma.This retrospective study was based on medical records from a single tertiary medical center. The records of 317 patients with esophageal squamous cell carcinoma treated with surgery or definitive chemoradiotherapy (CRT) between January 2009 and March 2016 were reviewed. Finally, we retrieved the data on 168 consecutive patients. These 168 patients were divided into 2 groups based on their endoscopic traversability findings: Group A (the endoscope traversable group), and Group B (the endoscope non-traversable group). We then retrospectively compared the clinical characteristics of these 2 groups.The endoscope non-traversable group (Group B) revealed an advanced clinical stage, a poor Eastern Cooperative Oncology Group (ECOG) score, a lower serum albumin level, a higher rate of requirement for esophageal stent insertion and definitive CRT as initial treatment than the endoscope traversable group (Group A). Patients with endoscope traversable cancer showed a significantly higher 3-year overall survival and 3-year relapse-free survival than patients who were endoscope non-traversable (53.8% vs 17.3%, P<.001 and 71.1% vs 45.3%, P=.003, respectively). Upon multivariate analysis of patients with locally advanced esophageal squamous cell carcinoma treated with definitive CRT, the serum albumin level <3.5g/dL and endoscopic non-traversability were significant negative factors of survival.Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma treated with definitive CRT is a significant prognostic factor.
引用
收藏
页数:10
相关论文
共 33 条
[1]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[2]   The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas [J].
Brücher, BLDM ;
Becker, K ;
Lordick, F ;
Fink, U ;
Sarbia, M ;
Stein, H ;
Busch, R ;
Zimmermann, F ;
Molls, M ;
Höfler, H ;
Siewert, JR .
CANCER, 2006, 106 (10) :2119-2127
[3]  
BYFIELD JE, 1989, INVEST NEW DRUG, V7, P111
[4]   MALIGNANT ESOPHAGEAL STRICTURES - STAGING ACCURACY OF ENDOSCOPIC ULTRASONOGRAPHY [J].
CATALANO, MF ;
VANDAM, J ;
SIVAK, MV .
GASTROINTESTINAL ENDOSCOPY, 1995, 41 (06) :535-539
[5]   Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy [J].
Cho, Charles J. ;
Song, Ho June ;
Lee, Gin Hyug ;
Choi, Kee Don ;
Kim, Yong-Hee ;
Ryu, Jin-Sook ;
Kim, Sung-Bae ;
Kim, Jong Hoon ;
Park, Seung-Il ;
Jung, Hwoon-Yong .
KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03) :443-451
[6]   Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].
Chou, I ;
Norman, AR ;
Cunningham, D ;
Waters, JS ;
Oates, J ;
Ross, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2395-2403
[7]   Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer [J].
Clavier, J. -B. ;
Antoni, D. ;
Atlani, D. ;
Ben Abdelghani, M. ;
Schumacher, C. ;
Dufour, P. ;
Kurtz, J. -E. ;
Noel, G. .
DISEASES OF THE ESOPHAGUS, 2014, 27 (06) :560-567
[8]   Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].
Cooper, JS ;
Guo, MD ;
Herskovic, A ;
Macdonald, JS ;
Martenson, JA ;
Al-Sarraf, M ;
Byhardt, R ;
Russell, AH ;
Beitler, JJ ;
Spencer, S ;
Asbell, SO ;
Graham, MV ;
Leichman, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627
[9]   Current management of esophageal cancer [J].
D'Journo, Xavier Benoit ;
Thomas, Pascal Alexandre .
JOURNAL OF THORACIC DISEASE, 2014, 6 :S253-S264
[10]  
Di Fiore F, 2006, WORLD J GASTROENTERO, V12, P4185